Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, and improvements to mRNA vaccines.
It has three active drug development programs: two innovative preclinical technology platforms – Sofra™ (improving mRNA technologies and autoimmunity) and Chroma™ (oncology), which provide the basis for active development of a growing pipeline of new proprietary drugs. Noxopharm also has a clinical oncology drug candidate Veyonda® currently in an investor-initiated trial.
Pharmorage has been the source of much of the technology in the Noxopharm preclinical pipeline.
Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.
Learn more about Noxopharm here
Veyonda® is currently not approved in Australia or any other country